Recently, synthetic biology company Beijing Huaguan Biotechnology Co., Ltd. (hereinafter referred to as Huaguan Bio) announced the completion of a Series C financing round worth several hundred million yuan. The round was jointly invested in by SoftBank Ventures Asia, Shunxi Fund, Changzhou Qihang Synthetic Biology Venture Capital Fund, SDIC Innovation, Yangtze River Capital, among others, with Luminous Capital acting as financial advisor.
It is reported that the newly raised funds will be primarily used for new product R&D in the pharmaceutical and broader health sectors, expansion of production facilities, and the construction of innovative collaboration platforms, injecting strong momentum into the company’s next stage of development.
According to Huaguan Bio’s official website, the company was founded in 2018 and focuses on upstream segments of the pharmaceutical and big health industries. It has established four R&D centers in Beijing, Nanjing, Chongqing, and Suzhou, built three technology platforms, and operates a hundred-ton-scale GMP production base in Inner Mongolia. The company mainly provides materials supply for innovative drugs, generic drugs, and health products, as well as technical services for drug R&D and regulatory registration, positioning itself as one of China’s leading manufacturers integrating synthetic biology and green chemistry.
In the cosmetic ingredients space, Huaguan Bio’s product portfolio includes widely used functional ingredients such as 4-butylresorcinol (commonly known as 577), Pro-xylane, and piroctone olamine. The company has achieved large-scale production of ingredients including Pro-xylane and is able to stably supply single S-enantiomer solid powder with a purity of up to 99.5%. It has also launched its own ingredient brand, “Yan Ru Yin,” and is currently researching a new dark spot–correcting active ingredient, Xian’anmituo (RN032H).
As a synthetic biology company, Huaguan Bio has been highly favored by capital markets. Since its establishment in 2018, it has completed six financing rounds, with investors including Hetang Capital, Acetyl Chemical, Kindawei, Cobio Pharmaceutical, and Zhongguancun Science City, among others.
Notably, at the end of 2025, Proya Cosmetics Co., Ltd. acquired a stake in Huaguan Bio, becoming one of its 28 shareholders. CHAILEEDO previously reported that Proya and Huaguan Bio are conducting collaborative research on dark spot correcting-related functional ingredients.
